Roger has >40 years of drug development experience, including the co-discovery of Lipitor®, the best-selling drug of all time with nearly $150B in sales. He founded two pharmaceutical companies with >$1B valuation/exit. Dr. Newton translates basic science to benefit humanity and is a prolific contributor to the development and commercialization of novel therapies and has served as a venture advisor and board member of several companies.

Spencer is a physician-executive with experience in clinical medicine, venture-backed startups, healthcare IT, and medical research. In his role as Chief Medical & Commercial Officer for ArborMetrix, a venture-backed healthcare research and data analytics company, he is responsible for new business generation and revenue and is instrumental in the delivery of real world evidence research initiatives.

Greg is a Professor of Medicine at McMaster University where he holds a Canada Research Chair, a J. Bruce Duncan Endowed Chair in Metabolic Diseases, and is Co-Director of the Centre for Metabolism, Obesity and Diabetes Research. He has published over 180 papers and has received outstanding scientific achievement awards from the Endocrine Society, the American Diabetes Association, Diabetes Canada, and the Canadian Institutes of Health Research.

Daniela has extensive expertise in pharmaceutical development, from drug design and early discovery to integrated drug development strategies for late-stage clinical development and NDA/market authorization. She is a co-inventor of composition of matter for several drugs in development and commercialization and has been a co-founder of several biotech organizations.

James is a Research Associate in the Department of Medicine and the Preclinical Trials Coordinator for the Centre of Metabolism, Obesity, and Diabetes Research at McMaster University. He has developed a number of preclinical models to examine the therapeutic potential of metabolic reprogramming for the treatment of liver cancer and has contributed to over 35 peer-reviewed manuscripts, including recently in the top journal Cell Metabolism.

Ajit has three decades of experience in advancing new chemical entities and biologics through preclinical testing in multiple therapeutic areas. He has served in leadership positions in nonclinical departments at Amgen, Bristol-Myers Squibb, Gemphire Therapeutics, Esperion Therapeutics, and was Executive Vice President at Piramal Life Sciences.

Avi has extensive experience in healthcare investment banking in a leading bulge bracket firm where he participated in over two dozen life sciences-focused M&A and IPO transactions with a combined deal value of more than $100BN. Prior to that, Avi spent time in consulting and private equity, and as an entrepreneur of two healthcare startups. Avi has an MBA from the University of Michigan and MS in Biomedical Engineering.